MX2012007153A - Nuevos anticuerpos antagonistas y sus fragmentos fab contra gpvi y sus usos. - Google Patents
Nuevos anticuerpos antagonistas y sus fragmentos fab contra gpvi y sus usos.Info
- Publication number
- MX2012007153A MX2012007153A MX2012007153A MX2012007153A MX2012007153A MX 2012007153 A MX2012007153 A MX 2012007153A MX 2012007153 A MX2012007153 A MX 2012007153A MX 2012007153 A MX2012007153 A MX 2012007153A MX 2012007153 A MX2012007153 A MX 2012007153A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- fab
- gpvi
- fragments
- fab fragments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Radiology & Medical Imaging (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención describe nuevos anticuerpos que se unen específicamente a la proteína de las membranas plaquetarias humanas Glicoproteína VI (GPVI) y sus fragmentos monovalentes o derivados. Los anticuerpos de la invención son anticuerpos de clon 390 de hibridoma y sus fragmentos de anticuerpo capaces de inducir un fenotipo de reducción de GPVI. Estos anticuerpos y fragmentos Fab pueden bloquear la unión de colágeno y evitar así la activación plaquetaria por colágeno. La invención también se refiere a clones de hibridoma y plásmidos de expresión para la producción de anticuerpos y fragmentos Fab descritos. La presente invención se refiere además a los usos de fragmentos de anticuerpos monovalentes para fabricar agentes de investigación, de diagnóstico e inmunoterapéuticos para el tratamiento de trombosis y otras vasculares. La invención también se refiere a Fab que soporta una molécula en el extremo C-terminal, así como método para evitar el reconocimiento de Fab por anticuerpos usando tal Fab modificado. La invención se refiere a un método para evitar la activación plaquetaria cuando se usa un Fab de anti-GPVI.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09306283A EP2336188A1 (en) | 2009-12-18 | 2009-12-18 | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
EP10305660A EP2397495A1 (en) | 2010-06-21 | 2010-06-21 | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
EP10305721A EP2402371A1 (en) | 2010-07-01 | 2010-07-01 | Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof |
PCT/IB2010/055917 WO2011073954A2 (en) | 2009-12-18 | 2010-12-17 | Novel antagonist antibodies and their fab fragments against gpvi and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2012007153A true MX2012007153A (es) | 2012-07-03 |
Family
ID=44060924
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014005133A MX347613B (es) | 2009-12-18 | 2010-12-17 | Nuevos anticuerpos antagonistas y sus fragmentos fab contra gpvi y sus usos. |
MX2012007153A MX2012007153A (es) | 2009-12-18 | 2010-12-17 | Nuevos anticuerpos antagonistas y sus fragmentos fab contra gpvi y sus usos. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014005133A MX347613B (es) | 2009-12-18 | 2010-12-17 | Nuevos anticuerpos antagonistas y sus fragmentos fab contra gpvi y sus usos. |
Country Status (29)
Country | Link |
---|---|
US (2) | US8852593B2 (es) |
EP (2) | EP2513147B1 (es) |
JP (1) | JP5843783B2 (es) |
KR (1) | KR20120102125A (es) |
CN (1) | CN102725309B (es) |
AR (1) | AR079645A1 (es) |
AU (1) | AU2010331807B2 (es) |
BR (1) | BR112012014975A2 (es) |
CA (1) | CA2784498A1 (es) |
CL (1) | CL2012001650A1 (es) |
CY (1) | CY1118389T1 (es) |
DK (1) | DK2513147T3 (es) |
EA (1) | EA201290525A1 (es) |
ES (1) | ES2596254T3 (es) |
HK (1) | HK1216537A1 (es) |
HR (1) | HRP20161298T1 (es) |
HU (1) | HUE029824T2 (es) |
IL (1) | IL220447A0 (es) |
LT (1) | LT2513147T (es) |
MA (1) | MA33930B1 (es) |
MX (2) | MX347613B (es) |
PL (1) | PL2513147T3 (es) |
PT (1) | PT2513147T (es) |
SG (2) | SG10201405259PA (es) |
SI (1) | SI2513147T1 (es) |
TW (1) | TW201132759A (es) |
UY (1) | UY33115A (es) |
WO (1) | WO2011073954A2 (es) |
ZA (1) | ZA201204421B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9139825B2 (en) | 2009-10-30 | 2015-09-22 | Novartis Ag | Universal fibronectin type III bottom-side binding domain libraries |
EA201290525A1 (ru) * | 2009-12-18 | 2013-01-30 | Санофи | Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения |
WO2012042026A1 (en) | 2010-09-30 | 2012-04-05 | Ablynx Nv | Biological materials related to c-met |
US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
ES2865068T3 (es) | 2011-01-14 | 2021-10-14 | Univ California | Anticuerpos terapéuticos contra la proteína ROR-1 y métodos para usarlos |
RS55775B2 (sr) * | 2011-06-23 | 2022-10-31 | Ablynx Nv | Tehnike za predviđanje, otkrivanje i smanjenje nespecifične proteinske interferencije u testovima koji uključuju pojedinačne varijabilne domene imunoglobulina |
PL2723771T3 (pl) | 2011-06-23 | 2020-04-30 | Ablynx Nv | Białka wiążące albuminy surowicy |
KR20220114104A (ko) * | 2011-06-23 | 2022-08-17 | 아블린쓰 엔.브이. | 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법 |
CA2845029A1 (en) * | 2011-08-17 | 2013-02-21 | Glaxo Group Limited | Modified proteins and peptides |
US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
EP2895510A2 (en) * | 2012-09-13 | 2015-07-22 | Novartis AG | Single domain antibody with c-terminal modification |
CN103396492A (zh) * | 2013-08-06 | 2013-11-20 | 安徽新标志科技有限公司 | 抗人血小板胶原蛋白受体的人源性单克隆抗体片段及其应用 |
MX2018001465A (es) | 2015-08-05 | 2019-01-31 | Acticor Biotech | Nuevos anticuerpos anti-gpvi humana y sus usos. |
EP3538552B1 (en) | 2016-11-14 | 2023-09-13 | MorphoSys AG | Fab molecules with a rodent hinge region and a non-rodent ch1 region |
KR102633644B1 (ko) * | 2017-02-03 | 2024-02-05 | 액티코어 바이오테크 | 항-인간 gpvi 항체를 이용한 혈소판 응집의 억제 |
CN112118869A (zh) * | 2018-05-16 | 2020-12-22 | 莫佛塞斯公司 | 靶向糖蛋白vi的抗体 |
GB202020602D0 (en) * | 2020-12-24 | 2021-02-10 | Univ Birmingham | Nanobody |
WO2022257106A1 (zh) * | 2021-06-11 | 2022-12-15 | 江苏丰华生物制药有限公司 | 一种人源化抗人GPVI单克隆抗体Fab片段及其应用 |
WO2023133470A2 (en) * | 2022-01-07 | 2023-07-13 | BioLegend, Inc. | Tmprss2 binding antibodies and antigen binding fragments thereof |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6498237B2 (en) | 1989-08-07 | 2002-12-24 | Peptech Limited | Tumor necrosis factor antibodies |
US5919452A (en) * | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
GB9109478D0 (en) * | 1991-05-02 | 1991-06-26 | Therapeutic Antibodies Inc | Antivenoms |
US7062219B2 (en) * | 1997-01-31 | 2006-06-13 | Odyssey Thera Inc. | Protein fragment complementation assays for high-throughput and high-content screening |
US7291714B1 (en) * | 1999-06-30 | 2007-11-06 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
US20040001826A1 (en) * | 1999-06-30 | 2004-01-01 | Millennium Pharmaceuticals, Inc. | Glycoprotein VI and uses thereof |
WO2001016321A1 (en) * | 1999-09-01 | 2001-03-08 | Otsuka Pharmaceutical Co., Ltd. | Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof |
AU1446801A (en) * | 1999-10-29 | 2001-05-14 | Rutgers, The State University Of New Jersey | Renilla reniformis green fluorescent protein |
AU2002211835A1 (en) * | 2000-09-29 | 2002-04-08 | Clinomics Laboratories, Inc. | Oncology tissue microarrays |
EP1224942A1 (en) * | 2001-01-23 | 2002-07-24 | Bernhard Dr. Nieswandt | Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases |
GB0130543D0 (en) * | 2001-12-20 | 2002-02-06 | Univ Cambridge Tech | Human antibodies and their use |
EP1538165A1 (en) * | 2003-12-03 | 2005-06-08 | Procorde GmbH | Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4 |
EP1369128A1 (en) * | 2002-06-07 | 2003-12-10 | Procorde GmbH | Inhibitors of glycoprotein VI and their therapeutic use |
GB0511590D0 (en) | 2005-06-07 | 2005-07-13 | Procorde Gmbh | Anti-thrombotic agents |
WO2005007800A2 (ja) * | 2003-07-18 | 2005-01-27 | Mochida Pharm Co Ltd | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
EP2332990A1 (en) * | 2004-03-19 | 2011-06-15 | Imclone LLC | Human anti-epidermal growth factor receptor antibody |
WO2005111083A2 (en) * | 2004-04-29 | 2005-11-24 | Otsuka Pharmaceutical Co., Ltd. | Antibodies specific for glycoprotein vi and methods of producing these antibodies |
EP1824979A2 (en) * | 2004-12-10 | 2007-08-29 | Trigen GmbH | Methods, products and uses involving platelets and/or the vasculature |
GB0502358D0 (en) * | 2005-02-04 | 2005-03-16 | Novartis Ag | Organic compounds |
US20090041783A1 (en) | 2005-04-28 | 2009-02-12 | Mochida Pharmaceutical Co., Ltd. | Anti-platelet membrane glycoprotein vi monoclonal antibody |
CA2606450A1 (en) * | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | Anti-platelet membrane glycoprotein vi monoclonal antibody |
JP5224707B2 (ja) * | 2005-04-28 | 2013-07-03 | 持田製薬株式会社 | 抗血小板膜糖蛋白質viモノクローナル抗体 |
WO2007091719A1 (ja) * | 2006-02-07 | 2007-08-16 | Mochida Pharmaceutical Co., Ltd. | 抗gpvi抗体の併用療法及び新規医薬用途 |
CA2646807A1 (en) * | 2006-03-31 | 2007-10-18 | Mochida Pharmaceutical Co., Ltd. | Novel platelet activation marker and method for determination thereof |
EP1916259A1 (en) * | 2006-10-26 | 2008-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti-glycoprotein VI SCFV fragment for treatment of thrombosis |
WO2009032661A1 (en) | 2007-08-29 | 2009-03-12 | Sanofi-Aventis | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses |
US20100297116A1 (en) * | 2007-10-31 | 2010-11-25 | Yongge Liu | Uses of a glycoprotein vi (gpvi) inhibitor |
EP2362783A2 (en) * | 2008-10-31 | 2011-09-07 | Biogen Idec MA Inc. | Light targeting molecules and uses thereof |
EA201290525A1 (ru) * | 2009-12-18 | 2013-01-30 | Санофи | Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения |
-
2010
- 2010-12-17 EA EA201290525A patent/EA201290525A1/ru unknown
- 2010-12-17 PT PT108130287T patent/PT2513147T/pt unknown
- 2010-12-17 EP EP10813028.7A patent/EP2513147B1/en active Active
- 2010-12-17 MA MA35073A patent/MA33930B1/fr unknown
- 2010-12-17 ES ES10813028.7T patent/ES2596254T3/es active Active
- 2010-12-17 JP JP2012543988A patent/JP5843783B2/ja not_active Expired - Fee Related
- 2010-12-17 CA CA2784498A patent/CA2784498A1/en not_active Abandoned
- 2010-12-17 LT LTEP10813028.7T patent/LT2513147T/lt unknown
- 2010-12-17 WO PCT/IB2010/055917 patent/WO2011073954A2/en active Application Filing
- 2010-12-17 DK DK10813028.7T patent/DK2513147T3/en active
- 2010-12-17 SG SG10201405259PA patent/SG10201405259PA/en unknown
- 2010-12-17 AR ARP100104712A patent/AR079645A1/es not_active Application Discontinuation
- 2010-12-17 MX MX2014005133A patent/MX347613B/es unknown
- 2010-12-17 KR KR1020127018655A patent/KR20120102125A/ko active IP Right Grant
- 2010-12-17 HU HUE10813028A patent/HUE029824T2/en unknown
- 2010-12-17 US US13/515,650 patent/US8852593B2/en active Active
- 2010-12-17 PL PL10813028T patent/PL2513147T3/pl unknown
- 2010-12-17 SG SG2012043956A patent/SG181707A1/en unknown
- 2010-12-17 UY UY33115A patent/UY33115A/es not_active Application Discontinuation
- 2010-12-17 SI SI201031298A patent/SI2513147T1/sl unknown
- 2010-12-17 CN CN201080061679.5A patent/CN102725309B/zh not_active Expired - Fee Related
- 2010-12-17 TW TW099144611A patent/TW201132759A/zh unknown
- 2010-12-17 BR BR112012014975A patent/BR112012014975A2/pt not_active IP Right Cessation
- 2010-12-17 MX MX2012007153A patent/MX2012007153A/es active IP Right Grant
- 2010-12-17 AU AU2010331807A patent/AU2010331807B2/en not_active Ceased
- 2010-12-17 EP EP15164863.1A patent/EP2933269A1/en not_active Withdrawn
-
2012
- 2012-06-15 ZA ZA2012/04421A patent/ZA201204421B/en unknown
- 2012-06-17 IL IL220447A patent/IL220447A0/en unknown
- 2012-06-18 CL CL2012001650A patent/CL2012001650A1/es unknown
-
2014
- 2014-08-29 US US14/473,504 patent/US9441040B2/en active Active
-
2016
- 2016-04-19 HK HK16104453.4A patent/HK1216537A1/zh unknown
- 2016-10-07 HR HRP20161298TT patent/HRP20161298T1/hr unknown
- 2016-10-19 CY CY20161101056T patent/CY1118389T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX347613B (es) | Nuevos anticuerpos antagonistas y sus fragmentos fab contra gpvi y sus usos. | |
EA201991099A1 (ru) | Антитела против cd73 и их применение | |
PH12019502561A1 (en) | Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4) | |
TN2011000528A1 (en) | Compositions and methods for antibodies targeting complement protein c3b | |
MY187263A (en) | Il-17 reception a antigen binding proteins | |
UA102867C2 (uk) | Антитіла до cxcr4 та їх застосування у лікуванні раку | |
TN2012000434A1 (en) | Biparatopic abeta binding polypeptides | |
EP2582722A4 (en) | ANTIBODIES AGAINST GD2 | |
MY151191A (en) | Novel antibodies | |
MX2018010331A (es) | Agentes de ligacion al factor de crecimiento endotelial vascular/ligando 4 similar a delta (vegf/dll4) y usos de los mismos. | |
TW200738748A (en) | Human monoclonal antibody human CD134 (OX40) and methods of making and using same | |
MX2007011064A (es) | Anticuerpos contra cd38 para tratamiento de mieloma multiple. | |
WO2011119979A3 (en) | Antibodies to muc16 and methods of use thereof | |
UA94452C2 (ru) | Гуманизированные моноклональные антитела к фактору роста гепатоцитов | |
MX2009005743A (es) | Nuevos anticuerpos monoclonales de globulomero anti-ab selectivos del conformero ab. | |
TN2012000466A1 (en) | Humanized anti cxcr4 antibodies for the treatment of cancer | |
MX2009006969A (es) | Purificacion de romidepsina. | |
UA113623C2 (uk) | Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi) | |
WO2008027739A3 (en) | Antibodies to ntb-a | |
WO2009051957A3 (en) | Antibodies to irem-1 | |
MY170404A (en) | Antigen binding proteins | |
MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
PH12020551012A1 (en) | Monoclonal antibodies and methods for using same | |
WO2012075342A3 (en) | Anti-bradykinin b2 receptor (bkb2r) monoclonal antibody | |
JOP20210168A1 (ar) | أجسام مضادة أحادية النسيلة ترتبط نوعيًا مع trbv9 بشري |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |